Physician profile
Holly Gower
NPI 1972235034
$2,269.55
in general payments reported to CMS, 2019-2025
25 companies · $786 in 2025
The $786 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $65.20 · 2023: $633 · 2024: $785 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,196 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,195.90 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $411.60 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $336.57 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $255.15 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $179.47 | 2022-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $113.53 | 2023-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $109.00 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.01 | 2024-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $81.19 | 2024-2025 | Otezla, Repatha, Repatha |
| Boston Scientific Corporation | $69.60 | 2025 | Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $68.22 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $66.09 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.95 | 2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $56.49 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $52.75 | 2022-2023 | Eliquis |
| Phathom Pharmaceuticals, INC. | $50.15 | 2024 | Voquezna |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $44.23 | 2023 | Seglentis, Livalo |
| Pfizer INC. | $39.09 | 2024-2025 | |
| Axsome Therapeutics, INC. | $33.81 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $31.22 | 2024-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $20.15 | 2025 | Austedo Xr |
| Lexicon Pharmaceuticals, INC. | $18.83 | 2023 | Inpefa |
| Aimmune Therapeutics, INC. | $15.80 | 2025 | Zenpep |
| Sumitomo Pharma America, INC. | $15.45 | 2023 | Gemtesa |
| Lundbeck LLC | $14.82 | 2024 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $14.38 | 2025 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Gower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.